演題詳細

ポスター / Poster

ポスター 8 (Poster 8) :AML:治療成績

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
政氏 伸夫 (Nobuo Masauji):1
1:北海道大学大学院保健科学研究院保健科学部門 病態解析学分野
 
前へ戻る

Treatment for elderly patients with acute myeloid leukemia (AML)

演題番号 : PS-1-55

木村 賢司 (Kenji Kimura):1、鐘野 勝洋 (Katsuhiro Shono):1、小野田 昌弘 (Masahiro Onoda):1、横田 朗 (Akira Yokota):1

1:Department of Hematology, Chiba Aoba Municipal Hospital

 

In elderly patients with AML, cure rates are very poor despite intensive chemotherapy (Cx). We retrospectively analyzed 104 patients aged over 55 years with AML in our institute between 2001 and 2012. The median age at diagnosis was 66 (56 to 95) years. 5-year overall survival (OS) was 29%, 40% and 13% in patients aged 56 to 60 (n=20), 61 to 65 (n=30) and 66 to 70 years (n=21), respectively. No patients aged over 70 years (n=33) survived more than 3 years. 33 patients, whose median age was 75 years, could not be intensively treated because of their poor condition, older age, or refusal. Remaining 71 patients, whose median age was 64 years, were treated with Cx and 42 patients achieved 1CR (CR rate 59%). Univariate analysis identified FAB classification (M0 or M6 or M7), MPO positivity (less than 50%), and cytogenetic risks (MRC, adverse), but not older age (more than 65 years), type of AML (not de novo), and WBC (higher than 20,000/μL), as poor prognostic factors for survival. When the outcome was compared in 35 patients who had no those risk factors (low risk group) to that in 36 patients who had one or more those risk factors (high risk group), OS was significantly better in low risk group (OS: 51% vs 12%, p <0.001). Reduced-intensity allogeneic stem cell transplantation (RIST) could not improve OS in both groups (RIST vs Cx: 33% vs 56% in low risk group, 11% vs 8% in high risk group). On the other hand maintenance Cx tended to improve OS in high risk group (p=0.50). The appropriate treatment strategies may improve the outcome in elderly patients with AML.

前へ戻る